Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ebola vaccine trial temporarily halted
Injection
A clinical trial of an Ebola vaccine has been temporarily halted after some patients complained of fever and muscle pain.

Volunteers complain of fever and muscle pain

A clinical trial of an Ebola vaccine has been temporarily halted as a precautionary measure after four patients complained of fever and muscle pain, the University of Geneva announced on Thursday (December 11).

In a statement, the hospital said: "All of these volunteers are in good health and are being monitored regularly by the team in charge of the study."

The hospital say that the reactions were expected and the participants were informed about them during the medical consultation which took place before their inclusion in the study.

The trials are set to resume again on 5 January, after checks to ensure that the joint pain symptoms in hands and feet are "benign and transient."

Scientists are racing to develop Ebola vaccines after the world's worst outbreak of the virus has killed more than 6,000 people in West Africa so far this year.

59 volunteers have been vaccinated so far in the human safety trials in Geneva, which began in November. The hospital says that initial results from the trials show that the vaccination is very well tolerated.

Similar studies are also underway in the United States, Canada, Germany and Gabon. 

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
CVS Group hit by cyber attack

CVS Group, which owns more than 450 veterinary practices in the UK, has been hit by a cyber attack.

In a statement, the group said the incident involved unauthorised external access to a limited number of its IT systems. As soon as the attack was discovered, the group took its IT systems temporarily offline, causing 'considerable operational disruption'.

It has warned that the security steps taken and ongoing plans to move its operational systems and IT infrastructure to the Cloud are likely to have an ongoing impact over a number of weeks.

Due to the risk that personal information was accessed, CVS has informed the Information Commissioner's Office. The company is working with third party consultants to investigate the incident.